Sign |
Subtypes
* |
|||
Luminal A |
Luminal B |
HER2 |
Basaloid |
|
Quantity ER+/HER2– cells |
87 % |
82 % |
20 % |
10 % |
Quantity HER2+ cells |
7 % |
15 % |
68 % |
2 % |
Quantity TNBC cells |
2 % |
1 % |
9 % |
80 % |
p53 path |
TP53 mutation (12 %) MDM2 increase (14 %) |
TP53 mutation (32 %) MDM2 increase (31 %) |
TP53 mutation (75 %) MDM2 increase (30 %) |
TP53 mutation (84 %) MDM2 increase (14 %) |
PIK3CA/PTEN path |
PIK3CA mutation (49 %) PTEN mutation/loss (13 %) INPP4B loss (9 %) |
PIK3CA mutation (32 %) PTEN mutation/loss (24 %) INPP4B loss (16 %) |
PIK3CA mutation (42 %) PTEN mutation/loss(19 %) INPP4B loss (30 %) |
PIK3CA mutation (7 %) PTEN mutation/loss(35 %) INPP4B loss (30 %) |
RB1 path |
High expression of RB1 Gain Cyclin D1 (29 %) Increase CDK4 (14 %) Low expression ofCDKN2C |
Gain Cyclin D1 (58 %) Increase CDK4 (25 %) |
Gain Cyclin D1 (38 %) Increase CDK4 (24 %) |
RB1 mutation/loss (20 %) Gain Cyclin E1 (9 %) High expression ofCDKN2A |
mRNA expression |
High ER cluster Low proliferation |
Low ER cluster High proliferation |
HER2-signature High proliferation |
Basal signature High proliferation |
Number of copies |
Increase diploids Many with quiet genomes |
Increase aneuploids Many with focal amplification |
Increase aneuploids High genomic instability |
Increase aneuploids High genomic instability |
DNA mutations |
PIK3CA (49 %) TP53 (12 %) GATA3 (14 %) MAP3K1 (14 %) |
TP53 (32 %) PIK3CA (32 %) MAP3K1 (5 %) |
TP53 (75 %) PIK3CA (42 %) PIK3R1 (8 %) |
TP53 (84 %) PIK3CA (7 %) |
DNA metilation |
Hyper-methylation |
Hypo-methylation |
||
Protein expression |
High estrogen signaling High cMYB Subtype responsive to RPPA |
Less estrogen signaling High FOXM1 and cMYC Subtype responsive to RPPA |
High expression of HER1 and HER2 |
High expression of DNA repair proteins, PTEN and loss of p-AKT signature |